The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to XORTX Therapeutics’ oxypurinol to treat autosomal dominant polycystic kidney disease (ADPKD) patients.

The ODD comes after XORTX submitted an application to the FDA along with a comprehensive package including an analysis of ADPKD patients and descriptions of those expected to benefit from the therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA ODD office determined that aberrant purine metabolism and high levels of uric acid suggest an injury mechanism in ADPKD patients and that treatment with XORLO may slow the progression of this injury.

The company noted that the ODD from the FDA is not an approval for the use of XORLO, a formulation of oxypurinol. It does, however, represent an important milestone in the discoveries made by the company, and a new process to slow the progression of kidney disease in ADPDK.

XORTX Therapeutics CEO Dr Allen Davidoff stated: “Orphan drug designation represents a major milestone for the company in pursuit of marketing approval for XORLO, our proprietary formulation of oxypurinol, and the XRx-008 programme for ADPKD.

“This designation was a significant and critical milestone for all of the staff and management at the company.

“Further, our potential partners indicated that it was a critical requirement underpinning their ongoing consideration of the XORLO programme.

“We look forward to our upcoming meeting with the FDA on 1 May 2023 to discuss our planned Phase III clinical programme for XORLO.”

Oxypurinol, a xanthine oxidase inhibitor, has key pharmacologic characteristics that are ideal for administration in ADPKD patients.